Clinical trials located in


Stanmore city is located in United Kingdom. Currently, 7 clinical trials are being conducted in this city.

Stanmore, located in the London Borough of Harrow, is a suburban area steeped in history and greenery. Known for its affluent status, it boasts the expansive Stanmore Common, a haven for nature enthusiasts. The area is also home to the historic Stanmore Hill, one of the highest points in London, offering panoramic views. Notably, Stanmore houses the Royal National Orthopaedic Hospital, a leading center for orthopedic treatment. The city’s rich past is encapsulated in the 14th-century St. John’s Church, showcasing its deep-rooted heritage.

  • CT-EU-00117169

    Study of Fidrisertib/IPN60130 in the treatment of Fibrodysplasia Ossificans Progressiva (FOP)

    The aim of this study is to test a new drug called fidrisertib (also known as IPN60130) to treat a rare disease called Fibrodysplasia Ossificans Progressiva, or FOP. FOP is a grave disease that causes bones to start growing in places they shouldn’t, such as muscles and soft tissues. This causes a lot of pain, swelling, and stiffness in the joints, making movement difficult.

    In the study, some participants will be given the new drug fidrisertib at two different doses, and others will be given a dummy treatment called a placebo. Researchers will monitor the situation closely, performing special tests called low-dose whole-body computed tomography (WBCT) to measure new bone growth. For some older participants, they may also use another type of test called fluorine-18-labeled sodium fluoride positron emission tomography – computed tomography to check bone growth.

    • IPN60130
    • placebo
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • A study on a new treatment for Hypophosphatasia

    This trial focuses is on evaluating the efficacy of a novel drug, ALXN1850, in assisting adolescents and adults diagnosed with Hypophosphatasia (HPP), a condition characterized by the deficiency of alkaline phosphatase enzyme. ALXN1850 aims to substitute this lacking enzyme and will be administered through subcutaneous injections. The primary objective is to assess the performance of the new drug in comparison to a placebo. The trial is conducted in a blinded manner, ensuring that participants remain unaware of whether they are receiving the actual drug or the placebo. The paramount goal is to ascertain the safety and effectiveness of the new treatment.

    • Efzimfotase alfa
  • Evaluating zilurgisertib for fibrodysplasia ossificans progressiva (FOP) treatment

    This clinical trial focuses on fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder where soft tissues progressively turn into bone, causing significant disability. The purpose of the study is to evaluate the efficacy, safety, and tolerability of Zilurgisertib.

    Participants will be randomly assigned to receive either Zilurgisertib or a placebo during a double-blind period lasting 24 weeks. Following this, all participants will receive Zilurgisertib in an open-label extension period for an additional 52 weeks. The study will closely monitor the development of new bone growth, assess the reduction in disease progression, and observe any adverse effects throughout the treatment periods. Participants will undergo regular health assessments, including physical exams, blood tests, and imaging studies to track the progress and effects of the treatment. The goal is to determine if Zilurgisertib can effectively slow or stop the abnormal bone formation characteristic of FOP, thereby improving the quality of life for those affected by this debilitating condition.

    • Zilurgisertib
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom: